Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.
Body weight/drug therapy
Cardio-renal-metabolic disease
GIP/GLP-1 receptor agonist
SURPASS clinical trials
Tirzepatide
Twincretin
Type 2 diabetes/drug therapy
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
19
05
2023
accepted:
08
09
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist ('twincretin')-a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits, combined with low rates of hypoglycaemia across a wide range of patient characteristics. The safety and adverse event rate for tirzepatide appears comparable to that of GLP-1 receptor agonists. Although results from dedicated cardiovascular (CV) and kidney trials are currently not available, information to date suggests that tirzepatide may have CV and kidney benefits in people with T2D. Tirzepatide has been approved for the treatment of T2D in the USA, United Arab Emirates, European Union, Japan and Australia. Here, we review how tirzepatide will fit into the T2D treatment continuum. We also consider future directions with tirzepatide in T2D, including its potential for targeting cardio-renal-metabolic disease in T2D, and discuss how tirzepatide-and other co-agonists in development-may challenge current approaches for management of T2D.
Identifiants
pubmed: 37824027
doi: 10.1007/s13300-023-01475-5
pii: 10.1007/s13300-023-01475-5
pmc: PMC10597955
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1997-2014Informations de copyright
© 2023. The Author(s).
Références
touchREV Endocrinol. 2022 Jun;18(1):10-19
pubmed: 35949358
Mol Metab. 2013 Dec 14;3(3):241-51
pubmed: 24749050
Diabetes Care. 2021 Jun;44(6):1433-1442
pubmed: 34016612
Diabetes Obes Metab. 2022 Dec;24(12):2283-2296
pubmed: 35929483
Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785
pubmed: 36152639
N Engl J Med. 2022 Sep 22;387(12):1063-1074
pubmed: 36129996
Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e007264
pubmed: 33176463
Lancet. 2023 Aug 26;402(10403):720-730
pubmed: 37364590
Front Endocrinol (Lausanne). 2021 Jul 07;12:645563
pubmed: 34305810
Cardiovasc Diabetol. 2017 Jan 13;16(1):6
pubmed: 28086882
Front Endocrinol (Lausanne). 2023 Jan 30;14:1111984
pubmed: 36793276
J Am Coll Cardiol. 2018 Feb 13;71(6):670-687
pubmed: 29420964
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
EClinicalMedicine. 2021 Aug 13;39:101088
pubmed: 34430840
Diabetes Care. 2013 Apr;36(4):894-900
pubmed: 23223349
Therapie. 2022 Jul-Aug;77(4):413-423
pubmed: 34782145
Diabetes Obes Metab. 2023 Apr;25(4):965-974
pubmed: 36514843
Diabetes Care. 2016 Apr;39(4):625-31
pubmed: 26681719
Mol Metab. 2018 Dec;18:3-14
pubmed: 30473097
Clin Diabetes. 2022 Jan;40(1):10-38
pubmed: 35221470
Diabetes Care. 2021 Jul 7;:
pubmed: 34244332
Nat Med. 2022 Mar;28(3):591-598
pubmed: 35210595
Endocrinology. 2021 Jul 1;162(7):
pubmed: 33782700
Lancet. 2022 Jan 22;399(10322):394-405
pubmed: 34600604
Diabetes Obes Metab. 2022 Dec;24(12):2341-2352
pubmed: 35848464
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Cardiovasc Diabetol. 2022 Nov 7;21(1):235
pubmed: 36344978
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
Front Endocrinol (Lausanne). 2021 Sep 08;12:735019
pubmed: 34566894
Diabetes Care. 2022 Nov 1;45(11):2753-2786
pubmed: 36148880
J Med Chem. 2021 Jan 28;64(2):1127-1138
pubmed: 33449689
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
N Engl J Med. 2022 Jul 21;387(3):205-216
pubmed: 35658024
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29
pubmed: 34310013
Nat Commun. 2022 Jun 24;13(1):3613
pubmed: 35750681
Circ Res. 2016 May 27;118(11):1844-55
pubmed: 27230645
Cardiovasc Diabetol. 2022 Sep 1;21(1):169
pubmed: 36050763
J Am Soc Hypertens. 2014 Aug;8(8):604-6
pubmed: 25151323
Lancet. 2021 Jul 10;398(10295):143-155
pubmed: 34186022
Endokrynol Pol. 2022;73(4):745-755
pubmed: 35593668
Diabetes Obes Metab. 2023 Jan;25(1):3-17
pubmed: 35929488
EClinicalMedicine. 2022 Oct 07;54:101691
pubmed: 36247927
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Diab Vasc Dis Res. 2017 May;14(3):172-183
pubmed: 28467203
Diabetes Res Clin Pract. 2018 Mar;137:137-148
pubmed: 29325774
Mol Metab. 2021 Apr;46:101090
pubmed: 32987188
Diabetes Obes Metab. 2019 Mar;21(3):454-466
pubmed: 30226298
N Engl J Med. 2022 Sep 22;387(12):1075-1088
pubmed: 36129997
Lancet. 2021 May 8;397(10286):1736-1748
pubmed: 33894838
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
Cardiorenal Med. 2011;1(1):5-12
pubmed: 22258461
PLoS One. 2022 Mar 4;17(3):e0264974
pubmed: 35245328
Future Cardiol. 2021 May;17(3):459-473
pubmed: 33820430
Lancet. 2021 Nov 13;398(10313):1811-1824
pubmed: 34672967
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Lancet. 2022 Nov 26;400(10366):1869-1881
pubmed: 36354040
JAMA. 2022 Feb 8;327(6):534-545
pubmed: 35133415
Lancet. 2021 Aug 14;398(10300):583-598
pubmed: 34370970